XLONasdaqPharmaceutical PreparationsFiscal year ends December 31
Xilio Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$8.33−0.22 (-2.57%)
Close on Oct 19, 2026
- Market cap
- $161.64M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
47.7%
3M of 6M shares
Institutional holders
25
10 new, 7 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
1 buys · 2 sales
Net bought $38.28K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Gilead Sciences Inc | 9,105,451 | 19.90% | 13G (passive) amendment | Dec 18, 2024 |
| Fhmlsp, L.P. | 8,141,017 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| Point72 Asset Management, L.P. | 8,000,000 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Yekaterina Chudnovsky | 7,000,000 | 15.90% | 13G (passive) | Jun 7, 2024 |
| BCLS II Equity Opportunities, LP | 664,021 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Orbimed Advisors LLC | 642,000 | 9.99% | 13G (passive) | Mar 31, 2026 |
| Michelle Ross | 628,866 | 9.50% | 13G (passive) amendment | Jun 30, 2026 |
| James N. Topper | 5,747,193 | 9.90% | 13G (passive) | Jun 5, 2025 |
| Coastlands Capital LLC | 5,346,069 | 9.99% | 13G (passive) | Dec 4, 2025 |
| Frazier Life Sciences Public Fund, L.P. | 4,676,472 | 6.70% | 13G (passive) amendment | Dec 31, 2025 |
| AbbVie Inc. | 4,347,826 | 9.00% | 13G (passive) | Feb 11, 2025 |
| StemPoint Capital LP | 4,000,000 | 7.20% | 13G (passive) | Sep 30, 2025 |
| Gilead Sciences, Inc. | 14,517,678 | 19.90% | 13G (passive) amendment | Dec 31, 2025 |
| Alex Silverstein | 1,142,862 | 9.90% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of XLO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 664,021 | 11.48% | $6.36M | – | 0.38% |
| Orbimed Advisors LLC | 592,300 | 10.24% | $5.67M | New | 0.11% |
| Frazier Life Sciences Management, L.P. | 422,505 | 7.31% | $4.05M | – | 0.09% |
| Stonepine Capital Management, LLC | 225,994 | 3.91% | $2.17M | +161,832 | 1.22% |
| Vanguard Capital Management LLC | 178,517 | 3.09% | $1.71M | +54,857 | 0.00% |
| Sio Capital Management, LLC | 152,464 | 2.64% | $1.46M | – | 0.24% |
| Adage Capital Partners Gp, L.L.C. | 111,541 | 1.93% | $1.07M | New | 0.00% |
| Merck & Co., Inc. | 105,982 | 1.83% | $1.02M | – | 0.19% |
| Renaissance Technologies LLC | 64,153 | 1.11% | $614.59K | +14,587 | 0.00% |
| Morgan Stanley | 56,954 | 0.98% | $545.62K | −539 | 0.00% |
| Geode Capital Management, LLC | 39,055 | 0.68% | $374.17K | +1,858 | 0.00% |
| Citadel Advisors LLC | 25,950 | 0.45% | $248.60K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 22,594 | 0.39% | $216.45K | −5,881 | 0.00% |
| Bridgeway Capital Management, LLC | 17,544 | 0.30% | $168.07K | New | 0.00% |
| Two Sigma Investments, LP | 14,544 | 0.25% | $139.33K | New | 0.00% |
| Velan Capital Investment Management LP | 14,285 | 0.25% | $136.85K | – | 0.08% |
| Gsa Capital Partners Llp | 13,590 | 0.24% | $130 | −3,356 | 0.01% |
| State Street Corp | 13,311 | 0.23% | $127.52K | – | 0.00% |
| Prelude Capital Management, LLC | 11,600 | 0.20% | $111.13K | New | 0.01% |
| BlackRock, Inc. | 8,757 | 0.15% | $83.89K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 25 | 3M | 47.7% | 10 / 4 | 4 / 7 | 1M | 0M |
| Q1 2026 | 23 | 2M | 34.1% | 23 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of XLO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 142,440 | 2.46% | $1.36M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 35,606 | 0.62% | $341.11K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 19,824 | 0.34% | $167.71K | 0.00% | May 31, 2026 |
| Ultra-Small Company Fund | 17,544 | 0.30% | $168.07K | 0.17% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 8,219 | 0.14% | $78.74K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 7,476 | 0.13% | $63.25K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 4,514 | 0.08% | $38.19K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 2,768 | 0.05% | $23.42K | 0.00% | May 31, 2026 |
| U.S. Vector Equity Portfolio | 1,507 | 0.03% | $13.73K | 0.00% | Jul 31, 2026 |
| Dimensional US Core Equity 1 ETF | 1,116 | 0.02% | $10.17K | 0.00% | Jul 31, 2026 |
| 1290 VT Micro Cap Portfolio | 538 | 0.01% | $5.15K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 471 | 0.01% | $4.51K | 0.00% | Jun 30, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 254 | 0.00% | $2.31K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Rene Russo | PRESIDENT AND CEO, Director | 325,422 | 5.63% | Jan 5, 2026 |
| Christopher James Frankenfield | Chief Financial Officer | 24,766 | 0.43% | Jan 5, 2026 |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | 6,371 | 0.11% | Jan 5, 2026 |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | 33,250 | 0.58% | Jan 5, 2026 |
| Yuan Xu | Director | – | – | Jun 12, 2026 |
| Sara Bonstein | Director | – | – | Jun 12, 2026 |
| Robert W. Ross | Director | – | – | Jun 12, 2026 |
| James Samuel Shannon | Director | 10,000 | 0.17% | Jun 12, 2026 |
| Aoife Brennan | Director | – | – | Jun 12, 2026 |
| Daniel J. Curran | Director | – | – | Jun 12, 2026 |
| Akintunde Olatokumbo Bello | Director | – | – | Jun 12, 2026 |
| Cheryl R. Blanchard | Director | – | – | Apr 16, 2026 |
| Christina Rossi | Director | – | – | Jun 12, 2025 |
| Paul J. Clancy | Director | – | – | Jun 12, 2025 |
| Gilead Sciences, Inc. | 10% owner | 9,105,451 | 157.47% | Feb 17, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| James Samuel Shannon Director | Mar 26, 2026 | Buy | +5,000 | $8.79 | $43.95K | 10,000 |
| Kevin M. Brennan SVP, FINANCE AND ACCOUNTING | Jan 2, 2026 | Sale(10b5-1 plan) | −1,826 | $0.64 | $1.17K | 6,371 |
| Christopher James Frankenfield Chief Financial Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −7,030 | $0.64 | $4.50K | 24,766 |
| Katarina Luptakova CHIEF MEDICAL OFFICER | Jan 1, 2026 | Option exercise | +16,625 | – | – | 33,250 |
| Rene Russo PRESIDENT AND CEO, Director | Jan 1, 2026 | Option exercise | +44,250 | – | – | 325,422 |
| Kevin M. Brennan SVP, FINANCE AND ACCOUNTING | Jan 1, 2026 | Option exercise | +5,000 | – | – | 8,197 |
| Christopher James Frankenfield Chief Financial Officer | Jan 1, 2026 | Option exercise | +19,375 | – | – | 31,796 |
| James Samuel Shannon Director | Jun 17, 2025 | Buy | +25,000 | $0.69 | $17.25K | 70,000 |
| Rene Russo PRESIDENT AND CEO, Director | Jun 16, 2025 | Buy | +36,289 | $0.68 | $24.68K | 281,172 |
| James Samuel Shannon Director | Jun 16, 2025 | Buy | +45,000 | $0.69 | $31.05K | 45,000 |
| Kevin M. Brennan SVP, FINANCE AND ACCOUNTING | Jan 2, 2025 | Sale(10b5-1 plan) | −1,803 | $0.98 | $1.77K | 3,197 |
| Christopher James Frankenfield Chief Financial Officer | Jan 2, 2025 | Sale(10b5-1 plan) | −6,954 | $0.98 | $6.81K | 12,421 |
| Kevin M. Brennan SVP, FINANCE AND ACCOUNTING | Jan 1, 2025 | Option exercise | +5,000 | – | – | 5,000 |
| Rene Russo PRESIDENT AND CEO, Director | Jan 1, 2025 | Option exercise | +44,250 | – | – | 244,883 |
| Katarina Luptakova CHIEF MEDICAL OFFICER | Jan 1, 2025 | Option exercise | +16,625 | – | – | 16,625 |
| Christopher James Frankenfield Chief Financial Officer | Jan 1, 2025 | Option exercise | +19,375 | – | – | 19,375 |
| Gilead Sciences, Inc. 10% owner | Dec 18, 2024 | Buy | +1,759,978 | $1.04 | $1.83M | 9,105,451 |
| Gilead Sciences, Inc. 10% owner | Apr 2, 2024 | Buy | +485,250 | $0.76 | $368.79K | 7,345,473 |
| Atlas Venture Fund XI, L.P. 10% owner | Feb 8, 2024 | Sale | −733 | $0.64 | $469 | 2,019,563 |
| Atlas Venture Fund XI, L.P. 10% owner | Feb 8, 2024 | Sale | −267 | $0.64 | $171 | 734,546 |
| Atlas Venture Associates Opportunity I, L.P. 10% owner | Jan 12, 2024 | Sale | −1,540 | $0.83 | $1.28K | 2,020,296 |
| Atlas Venture Associates Opportunity I, L.P. 10% owner | Jan 12, 2024 | Sale | −560 | $0.83 | $465 | 734,813 |
| Atlas Venture Associates Opportunity I, L.P. 10% owner | Jan 11, 2024 | Sale | −569 | $0.87 | $495 | 735,373 |
| Atlas Venture Associates Opportunity I, L.P. 10% owner | Jan 11, 2024 | Sale | −1,566 | $0.87 | $1.36K | 2,021,836 |
| BCIP Life Sciences Associates, LP 10% owner | Dec 10, 2021 | Buy | +21,812 | $9.56 | $208.52K | 2,802,225 |
| BCIP Life Sciences Associates, LP 10% owner | Dec 10, 2021 | Buy | +3,188 | $10.24 | $32.65K | 2,805,413 |
| BCIP Life Sciences Associates, LP 10% owner | Dec 9, 2021 | Buy | +4,011 | $9.84 | $39.47K | 2,780,413 |
| BCIP Life Sciences Associates, LP 10% owner | Dec 8, 2021 | Buy | +13,458 | $9.62 | $129.47K | 2,776,402 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Buy | +312,500 | $16.00 | $5.00M | 1,613,632 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Buy | +312,500 | $16.00 | $5.00M | 1,613,632 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Conversion | +302,588 | – | – | 1,301,132 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Conversion | +302,588 | – | – | 1,301,132 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Conversion | +998,544 | – | – | 998,544 |
| Impact Medicine Fund LP SV7 10% owner | Oct 26, 2021 | Conversion | +998,544 | – | – | 998,544 |
| (Imf) Gp Llp Sv7 10% owner | Oct 26, 2021 | Conversion | +302,588 | – | – | 1,301,132 |
| (Imf) Gp Llp Sv7 10% owner | Oct 26, 2021 | Conversion | +302,588 | – | – | 1,301,132 |
| (Imf) Gp Llp Sv7 10% owner | Oct 26, 2021 | Conversion | +998,544 | – | – | 998,544 |
| (Imf) Gp Llp Sv7 10% owner | Oct 26, 2021 | Conversion | +998,544 | – | – | 998,544 |
| Mgmt L.P. Deerfield 10% owner | Oct 26, 2021 | Conversion | +756,472 | – | – | 756,472 |
| Mgmt L.P. Deerfield 10% owner | Oct 26, 2021 | Conversion | +756,472 | – | – | 756,472 |
| Mgmt L.P. Deerfield 10% owner | Oct 26, 2021 | Buy | +387,500 | $16.00 | $6.20M | 1,143,972 |
| Mgmt L.P. Deerfield 10% owner | Oct 26, 2021 | Buy | +387,500 | $16.00 | $6.20M | 1,143,972 |
| Llc Fmr – | Oct 26, 2021 | Conversion | +789,473 | – | – | 815,788 |
| Llc Fmr – | Oct 26, 2021 | Conversion | +372,215 | – | – | 372,215 |
| Llc Fmr – | Oct 26, 2021 | Conversion | +28,703 | – | – | 1,530,990 |
| Llc Fmr – | Oct 26, 2021 | Conversion | +686,499 | – | – | 1,502,287 |
| Llc Fmr – | Oct 26, 2021 | Conversion | +4,465 | – | – | 4,465 |
| Ltd FIL – | Oct 26, 2021 | Conversion | +218,705 | – | – | 218,705 |
| Takeda Ventures, Inc. 10% owner | Oct 26, 2021 | Conversion | +1,475,121 | – | – | 1,475,121 |
| City Capital Llc Bay 10% owner | Oct 26, 2021 | Buy | +312,500 | $16.00 | $5.00M | 1,129,490 |
| City Capital Llc Bay 10% owner | Oct 26, 2021 | Conversion | +665,696 | – | – | 665,696 |
| City Capital Llc Bay 10% owner | Oct 26, 2021 | Conversion | +151,294 | – | – | 816,990 |
| RiverVest Venture Fund IV, L.P. 10% owner | Oct 26, 2021 | Buy | +250,000 | $16.00 | $4.00M | 1,441,444 |
| RiverVest Venture Fund IV, L.P. 10% owner | Oct 26, 2021 | Conversion | +832,120 | – | – | 832,120 |
| RiverVest Venture Fund IV, L.P. 10% owner | Oct 26, 2021 | Conversion | +359,324 | – | – | 1,191,444 |
| Atlas Venture Opportunity Fund I, L.P. 10% owner | Oct 26, 2021 | Buy | +187,500 | $16.00 | $3.00M | 735,942 |
| Atlas Venture Opportunity Fund I, L.P. 10% owner | Oct 26, 2021 | Conversion | +1,372,998 | – | – | 1,399,313 |
| Atlas Venture Opportunity Fund I, L.P. 10% owner | Oct 26, 2021 | Conversion | +624,089 | – | – | 2,023,402 |
| Atlas Venture Opportunity Fund I, L.P. 10% owner | Oct 26, 2021 | Conversion | +548,442 | – | – | 548,442 |
| Alexandria Venture Investments, LLC 10% owner | Oct 26, 2021 | Conversion | +166,423 | – | – | 166,423 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.